Fundraising FoxVeirulence
London, GB · 1 known investors
Find your way into Veirulence
Sign up to see every warm intro you have to Veirulence
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Veirulence team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.
Founders & leadership
RT
Rory Triniman, PhDFounderBefore starting Veirulence in 2024, Rory spent three years at Blue Matter, joining as an associate consultant in 2021 and moving into a consultant role in 2022. He completed his PhD at the University of Cambridge, where he researched from 2016 to 2021 and took part in the Medical iTeams programme.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- VEIRULENCE LTD
- Company number
- 14467295
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Nov 2022
- Registered office
- Flat 119 City Pavilion 33 Britton Street, London, EC1M 5UG
- Nature of business (SIC)
- 21100 — Manufacture of basic pharmaceutical products
- Accounts
- last made up to 30 Nov 2024 · next due 30 Nov 2026
- Confirmation statement
- last made up to 6 Nov 2025 · next due 20 Nov 2026
Current officers · 1
- Rory Clifford Triniman — director, appointed 7 Nov 2022
Source: Companies House public register · retrieved 20 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Veirulence do?
- Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.
- Who founded Veirulence?
- Veirulence was founded by Rory Triniman, PhD.
- Who are Veirulence's investors?
- Veirulence's investors include Oxford Technology Management.
- Where is Veirulence headquartered?
- Veirulence is headquartered in London, GB.